Schlieren (Zurich), Switzerland — August 14, 2025 — Leads & Copy — Kuros Biosciences reported its financial results for the first half of 2025, with total medical device sales rising 78% to $63.5 million. Direct MagnetOs sales increased 77% to $62.7 million. The group achieved its first operating profit, reaching $3.5 million, compared to an operating loss of $(0.2) million in H1 2024.
Total Group EBITDA reached $5.1 million in H1 2025, and adjusted EBITDA amounted to $7.8 million, equaling a margin of 12.3%. The company expects sales growth of at least 60% in 2025 and anticipates sales of between $220 million and $250 million by 2027.
Kuros Biosciences finalized a five-year strategic sales agent agreement with Medtronic for MagnetOs in U.S. sales territories. The company also received FDA clearance for its MagnetOs MIS Delivery System. ANVISA approved MagnetOs Putty for use in Brazil, expanding Kuros’ commercial presence in the South American spine market.
Kuros has secured a location in Atlanta for a new office and manufacturing facility to support diversified manufacturing and scale operations.
Chris Fair is the Chief Executive Officer of Kuros Biosciences.
Alexandre Müller, Investor Relations, Tel +41 43 268 32 31, IR@kurosbio.com
Daniel Geiger, Chief Financial Officer, Tel +41 44 733 47 41, daniel.geiger@kurosbio.com
Source: Kuros Biosciences
